Cipla Ltd.

Cipla has launched a mobile application designed to enable the first line of screening for asthma in India. According to the Global Burden of Disease report, the total burden of asthma in India is estimated to be around 34.3 million. India has a three-fold higher mortality rate and two-fold higher asthma-associated disability burden compared to the global proportion.

Earlier, the company had obtained regulatory approval from Central Drugs Standard Control Organisation (CDSCO) for the exclusive distribution and marketing of Afrezza (insulin human) Inhalation Powder in India. 

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.